de Bono JS et al. Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK). ESMO 2023;Abstract 1842TiP.

Getu AA et al. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer 2023;22(1):43. Abstract

Patel MR et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase 1/2 study. ESMO 2023;Abstract 690P.

Paz-Ares L et al. Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC). ESMO 2022;Abstract 1550TiP.

Shenderov E et al. MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase 1 cohort expansion. ESMO 2021;Abstract 620P.

Wang J et al. ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3 targeting antibody-drug conjugate, in patients with advanced solid tumors. ASCO 2023;Abstract 3017.

Zhao B et al. Immune checkpoint of B7-H3 in cancer: From immunology to clinical immunotherapy. J Hematol Oncol 2022;15(1):153. Abstract